$GMAB 0.50 Developing
- Date
- Jun 29, 2026
- Mentions
- 1
- Unique authors
- 1
- Sector
- biotech
- Stance
- neutral
- On card
- no
Sentiment history
bullish
neutral
mixed
bearish
line = signal
dashed = price
No sentiment history available for $GMAB yet.
Sentiment
neutral 1
Notable posts
-
neutral 13 eng
ABBVIE $ABBV REPORTS POSITIVE PHASE 3 EPCORITAMAB DATA IN LYMPHOMA AbbVie reported positive results from a Phase 3 trial of epcoritamab plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), per the company. Epcoritamab, marketed as Epkinly and developed with Genmab $GMAB, is a bispecific antibody already approved as a monotherapy for R/R DLBCL. DLBCL is the most common form of non-Hodgkin lymphoma.
view on X →
Only one day of history so far — the signal arc fills in as the daily job runs.